A study to understand the effect of unani formulation in da-us- sadaf (Plaque Psoriasis)

A randomised controlled trial to evaluate safety and efficacy of majoon e musaffi e azam and roghan e kamela versus calcitriol and methoxsalen solution in da us sadaf (plaque psoriasis). - nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103065

Enrollment

Registered

2026-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Majoon e musaffi e azam and roghan e kamela: Majoon e musaffi e azam (Oral) 6g with water BD for three Months. Barg e shahatra (Fumaria pulviflora) 200g, Post e halela zard (Terminalia

Eligibility

Inclusion criteria

Inclusion criteria: Positive auspitz sign, patients with symptoms like erythema, itching, thikening and scales. Pasi score less than 10.

Exclusion criteria

Exclusion criteria: Patients with other skin diseases, pregnancy and lactation. Subjects with psoriatic arthritis, patients with serious systemic diseases, patients not willing to give consent, patients with diabetes mellitus.

Design outcomes

Primary

Measure	Time frame
Pasi (psoriasis area and severity index) will be used before and after the treatment to rule out the outcome.Timepoint: 2nd, 4th, 6th, and 8th week post treatment.	—

Secondary

Measure	Time frame
Pasi (psoriasis area and severity index) will be used before and after the treatment to rule out the outcome.Timepoint: 2nd, 4th, 6th, and 8th week post treatment.	—

Countries

India

Contacts

Public ContactDr Reshma Mahjabeen

Government Nizamia Tibbi College and Hospital.

ahmedfarhath66@gmail.com9848195067

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026